Breaking News
April 19, 2019 - New insights into how vitamin D affects immune system
April 19, 2019 - Pfizer Announces Presentation of Data from a Phase 2 Study of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older
April 19, 2019 - Exercise can improve non-motor symptoms of Parkinson’s disease
April 19, 2019 - KZFPs play a key role in the regulation of human genome
April 19, 2019 - Extracts of ginkgo seeds show antibacterial activity on pathogens that cause skin infections
April 19, 2019 - Exercises and swimming goggles may reduce adverse effects on eye during long spaceflights
April 19, 2019 - Review suggests a reciprocal relationship between obesity and self-control
April 19, 2019 - Study identifies how enterococci bacteria cause antibiotic-resistant bloodstream infections
April 19, 2019 - Triple negative breast cancer develop resistance to chemotherapy by turning on molecular pathway
April 19, 2019 - Researchers identify key clues to brain and pancreas development
April 19, 2019 - Metformin May Cut Risk for Prematurity, Miscarriage in PCOS
April 19, 2019 - Obese mouse mothers trigger heart problems in offspring
April 19, 2019 - Research sheds light on how leukemia cells become resistant to drugs
April 19, 2019 - Health Tip: Stopping Nosebleeds – Drugs.com MedNews
April 19, 2019 - Pediatric endocrinologist gives iconic ‘Mona Lisa’ a second medical opinion
April 19, 2019 - Tapping patients’ wisdom for C-section pain management
April 18, 2019 - Why have autism rates ‘exploded’ in New Jersey?
April 18, 2019 - Microbiome science may help doctors to improve treatment for children with IBS
April 18, 2019 - New gene therapy cures babies with fatal ‘Bubble Boy’ disease
April 18, 2019 - No female mice? Scientists may still approve NIH grant
April 18, 2019 - What needs to be said about mental health in medicine
April 18, 2019 - Hickenlooper Expanded Medicaid, Created State-Run Marketplace To Insure Nearly All Coloradans
April 18, 2019 - Cancer cells grown in tumor-mimicking environment can help predict the effect of experimental drugs
April 18, 2019 - Albireo Announces FDA Clearance of IND to Commence Phase 2 Trial of Elobixibat for the Treatment of NAFLD/NASH
April 18, 2019 - Adhesive gel bonds to eye surface, could repair injuries without surgery
April 18, 2019 - The future of genomics: A podcast featuring Stanford geneticists
April 18, 2019 - As Syphilis Invades Rural America, A Fraying Health Safety Net Is Failing To Stop It
April 18, 2019 - APOE gene impacts sleep depending on gender and severity of Alzheimer’s
April 18, 2019 - PCORI’s newly approved awards focus on cancer pain and opioid use disorders
April 18, 2019 - New tool provides a standard way to measure effects of caring for survivors of TBI
April 18, 2019 - Smartphone use risks eye examination misdiagnosis
April 18, 2019 - How drug-resistant bugs grow in CF patients’ lungs
April 18, 2019 - Gordana Vunjak-Novakovic Elected to American Academy of Arts & Sciences
April 18, 2019 - Podcast: KHN’s ‘What The Health?’ You Have Questions, We Have Answers
April 18, 2019 - Diabetic drug shows potential to be repurposed as heart disease treatment for non-diabetic patients
April 18, 2019 - New estimation method assesses natural variations in sex ratio at birth
April 18, 2019 - UTA scientist receives $1.17 million grant for cancer research
April 18, 2019 - Coagulation factor VIIa prevents bleeds in hemophilia animal models
April 18, 2019 - Researchers identify risk factors for severe infection after knee replacement
April 18, 2019 - Mass drug administration can offer community-level protection against malaria
April 18, 2019 - FDA’s added sugar label could have substantial health and cost-saving benefits
April 18, 2019 - Researchers identify cause of inherited metabolic disorder
April 18, 2019 - Single strip of white paint not sufficient to protect people who ride bikes
April 18, 2019 - Partner status influences link between sexual problems and self-efficacy in breast cancer survivors
April 18, 2019 - Colorectal Neoplasia Risk Up for Hodgkin Lymphoma Survivors
April 18, 2019 - Rigid spine muscular dystrophy – Genetics Home Reference
April 18, 2019 - Simple bile acid blood test could tell risk of stillbirth
April 18, 2019 - Center for Experimental Therapeutics aims to enable all steps of drug development | News Center
April 18, 2019 - Falling for telephone scams could be an early sign of dementia
April 18, 2019 - Researchers annotate key neuronal proteins in lamprey genome
April 18, 2019 - Study uncovers new biomarker for personalized cancer treatments
April 18, 2019 - Scientists enter research collaboration to find a cure for cancer
April 18, 2019 - Study to compare benefits of tai chi and mindfulness meditation on MS symptoms
April 18, 2019 - Gestational diabetes during pregnancy may increase risk of type 1 diabetes in children
April 18, 2019 - Maternal age has no effect on IVF success, conclude researchers
April 18, 2019 - Is a New Remedy for Body Odor on the Horizon?
April 18, 2019 - Orthostatic hypotension – Genetics Home Reference
April 18, 2019 - Healing the heartbreak of stillbirth and newborn death
April 18, 2019 - New study calls healthiness of eggs into question
April 18, 2019 - Conference to highlight advances in human immune monitoring, bioinformatics | News Center
April 18, 2019 - Bacteria use viruses for self-recognition, study reveals
April 18, 2019 - New adhesive patch could help reduce post-heart attack muscle damage
April 18, 2019 - Researchers analyze the effects of dark play in a serious video game
April 18, 2019 - Scientists revive pig brain cells four hours after death
April 18, 2019 - Filial cannibalism and offspring abandonment may be forms of parental care
April 18, 2019 - Two proteins act in concert to maintain a healthy heart in mice, shows study
April 18, 2019 - Scientists create a functioning 3D printed heart
April 18, 2019 - Non-invasive vagus nerve stimulation improves disease symptoms in patients with rheumatoid arthritis
April 18, 2019 - Majority of men struggle to understand diagnosis and treatment of prostate cancer
April 18, 2019 - Researchers create new small molecules that may combat equine encephalitis viruses
April 18, 2019 - Animal-assisted therapy improves social behavior in patients with brain injuries
April 18, 2019 - Some viruses help protect harmful bacteria in CF patients | News Center
April 18, 2019 - Outpatient healthcare providers inappropriately prescribe antibiotics to 40% of patients
April 18, 2019 - Men who have a resting heart rate of 75 bpm are twice as likely to die early
April 18, 2019 - Novel serum biomarkers to detect NAFLD-related fibrosis
April 18, 2019 - New study delves deeper into individual genomic differences than ever before
April 18, 2019 - Gilead and Galapagos Announce Filgotinib Meets Primary Endpoint in the Phase 3 FINCH 3 Study in Methotrexate-Naïve Rheumatoid Arthritis Patients
April 18, 2019 - Emotional mirror neurons found in rats
April 18, 2019 - Sylvia Plevritis appointed chair of biomedical data science | News Center
April 18, 2019 - Cervical cancer subtype increasing in several subpopulations of women
Shorter Preventive TB Tx Effective for HIV+ Patients

Shorter Preventive TB Tx Effective for HIV+ Patients

image_pdfDownload PDFimage_print

Action Points

  • Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.
  • A shorter duration of preventive therapy for tuberculosis (TB) in HIV-positive individuals, a 1-month course of isoniazid/rifapentine, was comparable to the lengthier usual-care regimen for rates of TB and death.
  • Note that serious adverse events occurred in 5.6% of patients in the intervention group and 7.1% of the controls, but the difference was not significant.

BOSTON — A shorter duration of preventive therapy for tuberculosis (TB) in HIV-positive individuals was comparable to the lengthier usual-care regimen for rates of TB and death, a late-breaking phase III randomized trial presented here found.

A 1-month course of isoniazid/rifapentine, an antibiotic regimen for TB prevention, was found to be safe and effective when compared with the usual 9-month course of isoniazid alone in people with HIV infection, reported Richard E. Chaisson, MD, of Johns Hopkins University in Baltimore.

Constance Benson, MD, of the University of California San Diego, who moderated the press conference at the Conference on Retroviruses and Opportunistic Infections (CROI), but was not involved in the research, characterized these findings as having “the potential to immediately change clinical practice.”

In a separate statement released by the National Institutes of Health, Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases, agreed, saying that these results “offer people living with HIV who are at risk of developing active [TB] an additional, shorter-duration prevention option that is safe, effective and more convenient.”

At the press conference, Chaisson said that while prevention of TB with isoniazid is effective, “uptake has been appallingly bad.” He added that the longer the course of the therapy is, the more people stop taking it, and described “a sense of futility” among clinicians about this problem.

A shorter, 4-week course of rifapentine and isoniazid had shown promise in animal studies, the authors said, so they hypothesized it would be non-inferior to the usual 9-month standard of care. “The bottom line is,” Chaisson added, “it was.”

Participants were eligible if they were HIV-infected individuals age 13 or older with no evidence of active TB, who had either a positive TB skin or blood test (Interferon Gamma Release Assay, or IGRA) or lived in an area with a high burden of TB (prevalence ≥60/100,000 population). They were stratified by CD4-positive cell count and antiretroviral therapy (ART) use at entry.

After randomization, patients received either 300-mg isoniazid plus 450- to 600-mg rifapentine once daily for 4 weeks or 300-mg isoniazid daily for 9 months. They were then followed for 3 years after the last participant was enrolled. ART with efavirenz or nevirapine was permitted.

Overall, 1,488 patients in the intervention group and 1,498 patients in the control group were included in the analysis. More than half were women, two-thirds were black and median body mass index was 23.5. Median CD4 count was 470 cells/mm³, and half were on ART at entry. Around 20% had a positive TB skin or blood test. The primary endpoint was the incidence rate ratio of active TB, TB death, or death due to an unknown cause, and the non-inferiority margin was 1.25 per 100 person-years.

The intervention group had an incidence of 0.65 per 100 person-years and the control group had an incidence of 0.67 per 100 person-years (IRR difference 0.023, 95% CI -0.30 to 0.35).

Rates of the primary outcome were higher for patients not on ART at entry and those with a positive TB skin or blood test, but no difference between treatments was noted, the authors said. In addition, rates were higher in the intervention group among those with baseline CD4 counts of ≤250 mm3, but the difference was not statistically significant.

Serious adverse events occurred in 5.6% of patients in the intervention group and 7.1% of the controls, but the difference was not significant. The authors noted that safety was “similar” in both arms, with more hematologic toxicity in the intervention group and more liver and neurotoxicity in the control group.

Chaisson said that the study was unlikely to be replicated, but characterized this as a “large enough, clear enough answer that it can be acted upon.” He added that he hoped this therapy would be studied in people without HIV.

The next steps would be incorporating these findings into guidelines. Chaisson said that he shared his results with the World Health Organization and encouraged them to incorporate this into new guidelines, perhaps as an amendment, “as quickly as possible.”

Chaisson disclosed support from Otsuka.

Sanofi supplied study medications for this trial.

  • Reviewed by
    Robert Jasmer, MD Associate Clinical Professor of Medicine, University of California, San Francisco and Dorothy Caputo, MA, BSN, RN, Nurse Planner

2018-09-03T00:00:00-0400

last updated

Tagged with:

About author

Related Articles